Tres Uramigas shared a post on X:
“Disitamab vedotin + toripalimab improved OS and PFS vs Gem + platinum in patients with advanced UCIM with HER2 overexpression (IHC 1+, 2+, 3+).
Major changes in the treatment of urothelial cancer.”
Martin Zapata Laguad, Medical Oncologist and Internal Medicine Physician at National Cancer Institute of Colombia, commented this post:
“Excellent results, the question is uncertain… will there be a role for those low or very low HER2 expressers in the use of EV pembrolizumab?”
Toripalimab (Loqtorzi): Uses in Cancer, Side Effects, Dosage, Expectations, and More
Immunotherapy for Urothelial Cancer: Types, Success Rate, Side Effects and More.
